Special Issue "Latest Advances in Molecular and Cellular Immunotherapy"
Deadline for manuscript submissions: 1 September 2022.
Interests: cancer immunotherapy; cellular therapy; immune system reprograming; infection and cancer vaccines; adoptive cellular therapy in solid tumors; socio-economic impact of immunotherapy; microbiome in immunotherapy; cellular and molecular auto-immunity; immune-metabolism
Interests: immunology; cancer immunotherapy; cellular engineering; antibody engineering; hepatocellular carcinomas
The immune system’s role in infection and cancer therapy has been on the spotlight of medical breakthrough for the past decade. The advent of immune checkpoint blockade therapy, the success of genetic engineered T cells in hematological malignancies or the record-breaking development and approval of COVID-19 vaccines are true feats of modern medicine. The dust from these afore mentioned technological breakthroughs as yet to settle. We are striding towards completion of key trials that combine immunotherapy with other well-established treatment modalities. New mechanisms of action of these recently approved therapies keep being unveiled. Molecular fine-tuning, production scalability and the socio-economical impact of these new therapeutics are far from reaching maturity.
The journal Vaccines focuses not only on vaccination but also in immunological studies. I am pleased to invite you to a Special Issue focused on the “Latest advances in molecular and cellular immunotherapy” that aims at putting together a comprehensive collection that reports key-developments and emerging concepts in the field of immunotherapy.
In this Special Issue, original research articles and reviews are welcome. Pre-clinical and clinical research areas may include (but not limited to):
- cancer immunotherapy
- cellular therapy
- immune system reprograming
- infection and cancer vaccines
- adoptive cellular therapy in solid tumors
- socio-economic impact of immunotherapy
- microbiome in immunotherapy
- cellular and molecular auto-immunity
We look forward to receiving your contributions.
Dr. Bruno Loureiro Cadilha
Dr. Mohamed-Reda Benmebarek
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.